AnteoTech Limited

ADO

AU000000ADO8

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 11:18:12 2024-04-23 pm EDT			5-day change	1st Jan Change
0.023 ^AUD	0.00%		+4.55%	-36.11%

Apr. 08	Anteotech Seeks to Raise AU$6 Million From Share Placement; Shares Fall 26%	MT
Mar. 27	AnteoTech Receives AU$1.39 Million from Queensland Critical Minerals and Battery Technology Fund; Shares Down 3%	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about AnteoTech Limited

Anteotech Seeks to Raise AU$6 Million From Share Placement; Shares Fall 26%	Apr. 08	MT
AnteoTech Receives AU$1.39 Million from Queensland Critical Minerals and Battery Technology Fund; Shares Down 3%	Mar. 26	MT
AnteoTech Settles Patent Claims for AU$300,000	Mar. 04	MT
AnteoTech Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Anteotech Completes Construction of Anteo X Production Facility in Brisbane; Shares Climb 6%	Feb. 14	MT
AnteoTech Produces Anode Material Containing Proprietary Technology	Dec. 07	MT
AnteoTech Receives AU$3.8 Million R&D Tax Rebate; Shares Rise 3%	23-10-12	MT
AnteoTech Limited(ASX:ADO) dropped from S&P Global BMI Index	23-09-18	CI
AnteoTech Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
AnteoTech Limited Announces Appointment of Mr. Andrew Cook as Company Secretary, Effective from 28 August 2023	23-08-22	CI
Anteotech Limited Announces Appointment of Mr. Andrew Cook as Chief Financial Officer	23-08-22	CI
AnteoTech Halts Trade	23-07-24	MT
AnteoTech Limited Announces Retirement of Christopher Parker from the Board of Directors	23-06-27	CI
Anteotech to Undergo Major Rebranding; Shares Jump 10%	23-05-22	MT
Anteotech Limited Announces Changes to Leadership Team	23-04-30	CI
Anteotech Limited Announces Changes to Leadership Team	23-04-30	CI
AnteoTech Limited(ASX:ADO) dropped from S&P/ASX Emerging Companies Index	23-03-20	CI
AnteoTech Limited(ASX:ADO) dropped from S&P/ASX All Ordinaries Index	23-03-20	CI
Anteotech, Wyon to Collaborate on Silicon Anodes for Micro-Batteries	23-03-02	MT
Anteotech, Trinseo Europe Sign Deal to Develop New Product	23-02-22	MT
AnteoTech Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-21	CI
AnteoTech Appoints Chief Marketing Officer	23-02-15	MT
AnteoTech Limited Appoints Tsui Min Lian as Chief Marketing Officer, Effective 15 March 2023	23-02-14	CI
AnteoTech Receives AU$3.2 Million R&D Tax Refund	22-12-09	MT
AnteoTech Ltd Announces Halt of European Rat Clinical Trial to Refocus Initiatives	22-11-02	CI

AnteoTech Limited is an Australia-based surface chemistry company. The principal activities of the Company consist of research, development and commercialization of technologies with surface management applications. The activities are primarily focused on the commercialization of these technologies across applications in the Life Science and Clean Energy Technology markets. Its lead product, AnteoX, provides significant improvement in anode performance and the Company has partnered with global suppliers in lithium-ion battery manufacturing. The life sciences division services the point of care and diagnostics markets from global diagnostics companies to technology developers. Its AnteoBind provides advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy. It also offers bioconjugation and assay development services to assist point of care and diagnostics researchers and manufacturers in product development. It also offers ready-to-use kits.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ANTEOTECH LIMITED	-36.11%	35.94M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+47.81%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B